COSCIENS Biopharma Inc.
CSCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 93% | -51% | 8.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 49.3% | 41.1% | 58.7% | 60.9% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -97.9% | -39.1% | 42.1% | 31% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -111.1% | -48.8% | 23.7% | 19.6% |
| EPS Diluted | -5.93 | -1.89 | 2.5 | 1.69 |
| % Growth | -213.8% | -175.6% | 47.9% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | $0 |